

PATENT
86689.0006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Victor Brantl

Serial No: N/A

Filed: Herewith

For: USE OF RIBOFURANOSE
DERIVATIVES AGAINST
INFLAMMATORY BOWEL
DISEASES

Art Unit: N/A

Examiner: N/A

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to.

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450, on
July 2003

Date of Deposit

Wei-Ning Yang, Reg. No. 38,690

Name

07/ /2003

Signature

Date

**POWER OF ATTORNEY BY ASSIGNEE AND
EXCLUSION OF INVENTOR UNDER RULE 3.71**

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The undersigned, Dr. V. Brantl and Dr. P. Dörr, are representatives authorized to sign on behalf of the assignee of the entire interest in the above-identified subject application, **ICN PHARMACEUTICALS SWITZERLAND LTD** and hereby appoints:

STUART LUBITZ, Reg. No. 20,680; JOHN P. SCHERLACHER, Reg. No. 23,009; ALFRED A. D'ANDREA, JR., Reg. No. 27,752; WILLIAM J. KUBIDA, Reg. No. 29,664; MATTHEW BAILEY, Reg. No. 33,829; STUART T. LANGLEY, Reg. No. 33,940; CAROL W. BURTON, Reg. No. 35,465; STEVEN C. PETERSEN, Reg. No. 36,238; WILLIAM H. WRIGHT, Reg. No. 36,312; MICHAEL L. CRAPENHOFT, Reg. No. 37,115; DAVID LUBITZ, Reg. No. 38,229; WEI-NING YANG, Reg. No. 38,690; CELINE CROWSON, Reg. No. 40,357; STERLON R. MASON, Reg. No. 41,179; SARAH S. O'ROURKE, Reg. No. 41,226; LAWRENCE J. McCLURE, Reg. No. 44,228; ERIN P. MADILL, Reg. No. 46,893; BRIAN D. MARTIN, Reg. No. 47,771; KENTON B. ABEL, Reg. No. 49,051; ANTHONY J. ORLER, Reg. No. 41,232; YING CHEN, Reg. No. 50,193; PAUL B. HEYNSSSENS, Reg. No. 47,648; MINDA R. SCHECHTER, Reg. No. 38,296; WILLIAM R. THOMSON, JR., Reg. No. 20,719; DARIUSH G. ADLI, Reg. No. 51,386

PATENT
86689.0006

and all of the firm of Hogan & Hartson L.L.P. as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith; said appointment to be to the exclusion of the inventor and his attorney in accordance with the provisions of Rule 32 of the Patent Office Rules of Practice.


ICN PHARMACEUTICALS SWITZERLAND LTD, per 37 C.F.R. § 3.73(b), certifies that the evidentiary documents with respect to its ownership have been reviewed and that to the best of the undersigned's knowledge and belief, title is in the assignee seeking this action.


Please direct all telephone calls to **Wei-Ning Yang** at (213) 337-6700 and all correspondence relative to said application to the following address:

Wei-Ning Yang
HOGAN & HARTSON L.L.P.
500 South Grand Avenue, Suite 1900
Los Angeles, California 90071
Phone: 213-337-6700
Fax: 213-337-6701

**ASSIGNEE: ICN PHARMACEUTICALS
SWITZERLAND LTD**

Date: July 09, 2003

Signature: 
Title: Executive Vice President, R&D
Address: Rührbergstrasse 21
4127 Birsfelden
Switzerland

Signature: 
Title: Vice President, Regulatory Affairs
Address: Rührbergstrasse 21
4127 Birsfelden
Switzerland

PATENT (U.S.A.)
ATTORNEY'S DOCKET NO.
88880.0008

DECLARATION

☒ ORIGINAL
☐ CONTINUATION
☐ DIVISIONAL

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed as I below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

USE OF RIBOFURANOSF DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES

☒ the specification of which is attached hereto.

My residence, post office address and citizenship are as stated below next to my name.

I acknowledge my duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations § 1.56(a). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING Month Day Year	PRIORITY CLAIMED UNDER 35 U.S.C. 119
---------	--------------------	----------------------------------	---

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Serial No.)

(Filing Date)

(Status)

Send correspondence to:

Hogan & Hartson LLP.
500 South Grand Avenue, Suite 1900
Los Angeles, California 90071

DIRECT TELEPHONE CALLS TO:

Wei-Ning Yang
(213) 337-0700

(Please Print)

1	Name of Inventor Victor Brantl	Residence: CITY Schliengen	STATE or COUNTRY Germany
	Post Office Address 11, Durck Strasse 14, D 70418 Schliengen, Germany		CITIZENSHIP Germany
	Name of Inventor	Residence: CITY	STATE or COUNTRY
	Post Office Address		CITIZENSHIP
3	Name of Inventor	Residence: CITY	STATE or COUNTRY
	Post Office Address		CITIZENSHIP
4	Name of Inventor	Residence: CITY	STATE or COUNTRY
	Post Office Address		CITIZENSHIP [INVENTOR'S CITIZENSHIP]

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1 <i>[Signature]</i>	SIGNATURE OF INVENTOR 2
DATE July 9th, 2003	DATE
SIGNATURE OF INVENTOR 3	SIGNATURE OF INVENTOR 4
DATE	DATE

MILA - 00000/0000 - 170830 v1